IRMD - NASDAQ

IRadimed Corporation

IRMD·NASDAQ

$94.48

+5.1%

HealthcareMedical - Devices

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.21B

EPS1.7700

P/E Ratio53.38

Earnings Date07/30/2026

108.78M

Assets

11%

3Y+27.0%

5Y+53.0%

10Y+192.0%

14.16M

Total Liabilities

23%

3Y+20.0%

5Y+46.0%

10Y+167.0%

94.62M

Total Equity

3Y+28.0%

5Y+54.0%

10Y+197.0%

IRadimed Corporation Funding & Solvency Profile

IRMD · NASDAQ

Current Assets

Cash & Cash Equivalents51.16M

Net Receivables13.67M

Inventory11.62M

Other Current Assets4.76M

Total Current Assets81 M

Non-Current Assets

Property, Plant & Equipment23.86M

Goodwill & Intangible Assets3.38M

Long-Term Investments0.00

Other Non-Current Assets239.00K

Total Non-Current Assets24 M

Total Assets

108.78M

Financial Health Analysis

Current Ratio

7.98x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.15x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

71 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

75% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

IRadimed Corporation Balance Sheet

IRMD • NASDAQ

IRadimed Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	51.2M	52.2M	49.8M	58M	62M	50.1M	43.5M	28M	18.2M	17.7M	19.4M	9.5M	2.5M	1.7M
Short-Term Investments	0.0	0.0	0.0	0.0	501.9K	1.9M	2.8M	6.3M	8.1M	8M	7.6M	7.9M	246.2K	250.8K
Cash & Short-Term Investments	51.2M	52.2M	49.8M	58M	62.5M	52M	46.3M	34.4M	26.3M	25.7M	27M	17.4M	2.7M	1.9M
Net Receivables	13.7M	10.6M	12.2M	13.3M	5.1M	4.6M	7.3M	4.2M	3.8M	3.8M	3.9M	2M	2M	1.6M
Accounts Receivables	13.7M	10.6M	12.2M	13.3M	5.1M	4.6M	7.3M	4.2M	3.8M	3.8M	3.9M	2M	2M	1.6M
Inventory	11.6M	10.4M	12.8M	5.4M	4.3M	3.9M	3.6M	4.1M	4.2M	3.9M	2.4M	2.1M	1.3M	1.4M
Prepaids	0.0	0.0	0.0	254.1K	3.3M	2.5M	1.4M	1.4M	127.9K	151.8K	274K	320.9K	170.5K	0.0
Other Current Assets	4.8M	2M	1.2M	631K	1M	771.7K	407.8K	526.8K	648.9K	674.8K	459.4K	392.9K	183.6K	77.2K
Total Current Assets	81.2M	75.2M	76M	77.5M	76.2M	63.7M	59M	44.5M	35.1M	34.2M	34M	22.2M	6.4M	5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	23.9M	17M	11.3M	4.6M	4.6M	4.8M	5M	1.9M	1.9M	1.5M	905.6K	794.8K	327.3K	265.6K
Intangible Assets	3.4M	3.1M	2.5M	2.1M	1.1M	960.9K	860.1K	832.5K	885.5K	918.7K	175.5K	250.8K	267K	276K
Goodwill & Intangible Assets	3.4M	3.1M	2.5M	2.1M	1.1M	960.9K	860.1K	832.5K	885.5K	918.7K	175.5K	250.8K	267K	276K
Tax Assets	94K	2.8M	2.1M	700.9K	765.1K	1.3M	1.7M	1.1M	950.4K	477.5K	88.4K	76.6K	0.0	12.5K
Other Non-Current Assets	239K	198.9K	181.4K	648.7K	201.3K	262K	232K	109.8K	200.2K	173.8K	124.2K	19.7K	8.2K	3.2K
Total Non-Current Assets	27.6M	23.1M	16.2M	8M	6.6M	7.3M	7.8M	3.9M	3.9M	3M	1.3M	1.1M	602.6K	557.4K
Total Assets	108.8M	98.3M	92.2M	85.5M	82.9M	71.1M	66.7M	48.4M	39M	37.2M	35.2M	23.3M	7M	5.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.6M	2.1M	10.2M	1.9M	923.2K	761K	1.6M	772.5K	669.5K	1.3M	1M	629.2K	571.2K	816K
Accounts Payable	1.8M	1.9M	1.9M	1.8M	782.9K	657.1K	993.7K	772.5K	656.7K	1.1M	1M	629.2K	427.5K	408.4K
Other Payables	1.8M	163K	8.3M	121.9K	140.3K	104K	596.6K	0.0	12.7K	192K	0.0	0.0	143.8K	407.6K
Accrued Expenses	3.2M	3.8M	2.8M	2.9M	2.8M	1.7M	2.2M	1.8M	1.5M	1M	1.3M	1.2M	655.4K	541.3K
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3K	519.7K
Capital Lease Obligations (Current)	0.0	153.3K	428K	293.5K	276.6K	255.7K	240.8K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	163K	353.3K	121.9K	140.3K	104K	596.6K	133K	122.2K	311.1K	30.7K	65.8K	143.8K	407.6K
Deferred Revenue	2.9M	2.3M	2.6M	3.4M	2.6M	1.9M	1.7M	1.8M	1.6M	1M	536.9K	308.3K	207.4K	389.4K
Other Current Liabilities	457K	268.3K	367.5K	94K	255.3K	236.5K	190.2K	315.9K	278.6K	280.6K	64.8K	93.7K	12K	64.9K
Total Current Liabilities	10.2M	8.5M	16.3M	8.6M	6.8M	4.9M	5.9M	4.7M	4.1M	3.7M	2.9M	2.3M	1.5M	2.3M
NON-CURRENT LIABILITIES
Deferred Revenue (Non-Current)	4M	3M	2.8M	1.4M	1.7M	2.3M	2.6M	1.8M	2M	1.6M	415.8K	142.9K	57.7K	2.7K
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	374.2K	0.0	54.1K	0.0
Total Non-Current Liabilities	4M	3M	4.4M	3.3M	3.9M	4.8M	5.3M	1.8M	2M	1.6M	415.8K	142.9K	111.8K	2.7K
Capital Lease Obligations	0.0	154.7K	2M	2.2M	2.5M	2.7M	3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	14.2M	11.5M	20.7M	11.8M	10.7M	9.7M	11.2M	6.5M	6.1M	5.3M	3.3M	2.4M	1.6M	2.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	140.0	140.0
Common Stock	1K	1.3K	1.3K	1.3K	1.3K	1.2K	1.2K	1.1K	1.1K	1.1K	1.1K	1.1K	700.0	700.0
Additional Paid-In Capital	30.4M	30M	28.2M	26.4M	25.2M	23.7M	19.2M	15.3M	12.6M	12.1M	19.3M	15.8M	2.3M	2.1M
Retained Earnings	64.2M	56.8M	43.3M	47.3M	47M	37.7M	36.3M	26.7M	20.4M	19.9M	12.7M	5.1M	3.1M	1.1M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	17K	37.1K	30.4K	-42.2K	-48.9K	-36.8K	-55.3K	-21.5K	924.0	7.1K
Total Stockholders' Equity	94.6M	86.8M	71.4M	73.7M	72.2M	61.4M	55.5M	41.9M	32.9M	31.9M	31.9M	20.9M	5.4M	3.2M
Total Equity	94.6M	86.8M	71.4M	73.7M	72.2M	61.4M	55.5M	41.9M	32.9M	31.9M	31.9M	20.9M	5.4M	3.2M
SUMMARY
Total Liabilities & Equity	108.8M	98.3M	92.2M	85.5M	82.9M	71.1M	66.7M	48.4M	39M	37.2M	35.2M	23.3M	7M	5.6M
Total Investments	0.0	0.0	0.0	0.0	501.9K	1.9M	2.8M	6.3M	8.1M	8M	7.6M	7.9M	246.2K	250.8K
Total Debt	0.0	154.7K	2M	2.2M	2.5M	2.7M	3M	0.0	0.0	0.0	0.0	0.0	6.3K	519.7K
Net Debt	-51.2M	-52.1M	-47.7M	-55.8M	-59.5M	-47.4M	-40.5M	-28M	-18.2M	-17.7M	-19.4M	-9.5M	-2.5M	-1.2M
Shares Outstanding	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156	12,721,156

SEC Filings

IRMD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 01, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 01, 2026	May 01, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 06, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 10, 2026	February 10, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 05, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 03, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing
10-K/A 10-K/A 2024 FY (Amended) FY	September 03, 2025	December 31, 2024	2024	View Filing
8-K 8-K 2025 N/A	September 02, 2025	August 27, 2025	2025	View Filing

Showing 1 to 10 of 190 filings

Related Guides

Blog Categories

Continue your IRMD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.